The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy
出版年份 2019 全文链接
标题
The Emerging Role of ESR1 Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine Therapy
作者
关键词
-
出版物
Cancers
Volume 11, Issue 12, Pages 1894
出版商
MDPI AG
发表日期
2019-11-28
DOI
10.3390/cancers11121894
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
- (2019) Aradhana Rani et al. Frontiers in Endocrinology
- Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
- (2018) G N Hortobagyi et al. ANNALS OF ONCOLOGY
- Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer
- (2018) R J Hartmaier et al. ANNALS OF ONCOLOGY
- A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2−Advanced Breast Cancer
- (2018) Erika P. Hamilton et al. CLINICAL CANCER RESEARCH
- Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer
- (2018) Takashi Takeshita et al. Molecular Cancer
- Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment
- (2018) Hitisha K. Patel et al. PHARMACOLOGY & THERAPEUTICS
- Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer
- (2018) Ben O’Leary et al. Nature Communications
- Discovery of Selective Estrogen Receptor Covalent Antagonists (SERCAs) for the treatment of ERa(WT) and ERa(MUT) breast cancer.
- (2018) Xiaoling Puyang et al. Cancer Discovery
- The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
- (2018) Pedram Razavi et al. CANCER CELL
- Lasofoxifene efficacy in a mammary intraductal (MIND) xenograft model of ERα+ breast cancer.
- (2018) Muriel Laine et al. JOURNAL OF CLINICAL ONCOLOGY
- PADA-1: A randomized, open label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with hormone therapy driven by circulating DNA ESR1 mutation monitoring in ER-positive, HER2-negative metastatic breast cancer patients.
- (2018) Francois Clement Bidard et al. JOURNAL OF CLINICAL ONCOLOGY
- The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial
- (2018) Ben O'Leary et al. Cancer Discovery
- Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: a meta-analysis
- (2018) Kai Zhang et al. Cancer Management and Research
- Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer in PALOMA-3
- (2018) Massimo Cristofanilli et al. EUROPEAN JOURNAL OF CANCER
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
- (2018) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers
- (2016) D. Fumagalli et al. ANNALS OF ONCOLOGY
- AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models
- (2016) H. M. Weir et al. CANCER RESEARCH
- PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
- (2016) Charlotte Fribbens et al. JOURNAL OF CLINICAL ONCOLOGY
- Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Ian E Krop et al. LANCET ONCOLOGY
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
- (2016) Jill M. Spoerke et al. Nature Communications
- ActivatingESR1Mutations Differentially Affect the Efficacy of ER Antagonists
- (2016) Weiyi Toy et al. Cancer Discovery
- Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor
- (2016) Florian Clatot et al. Oncotarget
- Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole
- (2016) Rekha Gyanchandani et al. Oncotarget
- The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
- (2016) James D Joseph et al. eLife
- Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer
- (2016) Sarat Chandarlapaty et al. JAMA Oncology
- Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer
- (2015) S. E. Wardell et al. CLINICAL CANCER RESEARCH
- Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts
- (2015) Andiliy Lai et al. JOURNAL OF MEDICINAL CHEMISTRY
- Estrogen receptors in breast carcinogenesis and endocrine therapy
- (2015) Bo Huang et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
- (2015) Rinath Jeselsohn et al. Nature Reviews Clinical Oncology
- Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer
- (2015) Gaia Schiavon et al. Science Translational Medicine
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†
- (2014) M. Piccart et al. ANNALS OF ONCOLOGY
- Abstract OT3-2-07: Phase I study of ARN-810, a novel selective estrogen receptor degrader, in post-menopausal women with locally advanced or metastatic estrogen receptor positive breast cancer
- (2014) IA Mayer et al. CANCER RESEARCH
- Emergence of Constitutively Active Estrogen Receptor- Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer
- (2014) R. Jeselsohn et al. CLINICAL CANCER RESEARCH
- Recurrent ESR1–CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers
- (2014) Jamunarani Veeraraghavan et al. Nature Communications
- D538G Mutation in Estrogen Receptor- : A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer
- (2013) K. Merenbakh-Lamin et al. CANCER RESEARCH
- Bazedoxifene Exhibits Antiestrogenic Activity in Animal Models of Tamoxifen-Resistant Breast Cancer: Implications for Treatment of Advanced Disease
- (2013) S. E. Wardell et al. CLINICAL CANCER RESEARCH
- Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial
- (2013) Stephen RD Johnston et al. LANCET ONCOLOGY
- Enhanced PI3K p110 Signaling Confers Acquired Lapatinib Resistance That Can Be Effectively Reversed by a p110 -Selective PI3K Inhibitor
- (2013) S. W. Brady et al. MOLECULAR CANCER THERAPEUTICS
- ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
- (2013) Weiyi Toy et al. NATURE GENETICS
- Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
- (2013) Shunqiang Li et al. Cell Reports
- Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer
- (2013) L-Y Huw et al. Oncogenesis
- Estrogen receptors and human disease: an update
- (2012) Katherine A. Burns et al. ARCHIVES OF TOXICOLOGY
- Elusive Extranuclear Estrogen Receptors in Breast Cancer
- (2012) E. R. Levin CLINICAL CANCER RESEARCH
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of Endocrine Resistance in Breast Cancer
- (2010) C. Kent Osborne et al. Annual Review of Medicine
- Growth factor stimulation induces a distinct ER cistrome underlying breast cancer endocrine resistance
- (2010) M. Lupien et al. GENES & DEVELOPMENT
- Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer
- (2010) Angelo Di Leo et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic versus predictive value of biomarkers in oncology
- (2008) C.N.A.M. Oldenhuis et al. EUROPEAN JOURNAL OF CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now